Impact of timing of atrial fibrillation, CHA


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
11 2020
Historique:
received: 03 08 2020
revised: 23 10 2020
accepted: 09 11 2020
entrez: 27 11 2020
pubmed: 28 11 2020
medline: 23 7 2021
Statut: ppublish

Résumé

To investigate timing and age distribution of atrial fibrillation (AF) in selected oncology patients, and the impact of AF timing, CHA This is a retrospective cohort study of oncology patients referred to the cardio-oncology service from 2011 to 2018 for echocardiographic cardiosurveillance and/or pre-existing cardiovascular risk factor/disease management. Rates of first AF diagnosis was assessed using a parametric multiphase hazard model (predictive modelling) and non-parametrically by Kaplan-Meier with transformations tested using a bootstrap methodology. Among 6754 patients identified, 174 patients had their first AF diagnosis This study reports a nuanced/complex relationship between AF and cancer. First diagnosis of AF in patients with cancer was more common at/early after cancer diagnosis, especially in older patients and those exposed to cardiotoxic treatment. Pre-existing AF or a diagnosis of AF within 3 years after cancer diagnosis carried a negative prognosis. CHA

Identifiants

pubmed: 33243931
pii: openhrt-2020-001412
doi: 10.1136/openhrt-2020-001412
pmc: PMC7692982
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Prev Chronic Dis. 2016 Nov 17;13:E157
pubmed: 27854420
J Cardiothorac Surg. 2012 Jan 10;7:4
pubmed: 22233837
PLoS One. 2016 May 05;11(5):e0154931
pubmed: 27148877
Am J Cardiol. 2015 Apr 15;115(8):1090-4
pubmed: 25711434
Heart Rhythm. 2015 Mar;12(3):554-559
pubmed: 25460854
Am J Cardiol. 2020 Dec 15;137:118-124
pubmed: 32991858
JAMA Netw Open. 2019 Sep 4;2(9):e1911838
pubmed: 31539076
Intern Emerg Med. 2008 Sep;3(3):227-31
pubmed: 18320149
Curr Oncol Rep. 2019 Apr 4;21(5):45
pubmed: 30949848
Circulation. 2004 Aug 31;110(9):1042-6
pubmed: 15313941
Eur Heart J. 2012 Jun;33(12):1500-10
pubmed: 22246443
Circulation. 2017 Oct 24;136(17):1588-1597
pubmed: 29038167
J Clin Epidemiol. 2016 Nov;79:167-168
pubmed: 27373196
J Cardiovasc Electrophysiol. 2011 Aug;22(8):839-45
pubmed: 21410581
J Epidemiol. 2016;26(4):191-8
pubmed: 26639750
Int J Cardiol. 2016 Sep 15;219:186-94
pubmed: 27327505
Clin Epidemiol. 2017 Jan 24;9:53-62
pubmed: 28182159
Circulation. 2013 Sep 3;128(10):1085-93
pubmed: 23908348
Circulation. 1998 Sep 8;98(10):946-52
pubmed: 9737513
JACC CardioOncol. 2020 Aug 28;2(3):400-410
pubmed: 34396248
Front Pharmacol. 2018 Oct 16;9:1058
pubmed: 30386232
Circulation. 2006 Jul 11;114(2):119-25
pubmed: 16818816
PLoS One. 2018 Oct 5;13(10):e0205454
pubmed: 30289944
Circulation. 2018 Feb 20;137(8):e30-e66
pubmed: 29437116
BMC Cancer. 2019 Nov 14;19(1):1105
pubmed: 31726997
Circulation. 2014 Feb 25;129(8):837-47
pubmed: 24345399
J Am Coll Cardiol. 2014 Mar 18;63(10):945-53
pubmed: 24361314
Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719860676
pubmed: 31319783
Circulation. 2018 Mar 6;137(10):1027-1038
pubmed: 29129827
J Am Coll Cardiol. 2015 Jun 30;65(25):2739-46
pubmed: 26112199

Auteurs

Muzna Hussain (M)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Centre for Experimental Medicine, Queen's University Belfast, Belfast, County Antrim, UK.

Rabel Misbah (R)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Eoin Donnellan (E)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Saqer Alkharabsheh (S)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Yuan Hou (Y)

Department of Genomic Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Feixiong Cheng (F)

Department of Genomic Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Michael Crookshanks (M)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Chris J Watson (CJ)

Centre for Experimental Medicine, Queen's University Belfast, Belfast, County Antrim, UK.

Andrew J Toth (AJ)

Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States.

Penny Houghtaling (P)

Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, United States.

Rohit Moudgil (R)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

G Thomas Budd (GT)

Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.

W H Wilson Tang (WHW)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Deborah H Kwon (DH)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Wael Jaber (W)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Brian Griffin (B)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Mohamad Kanj (M)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Patrick Collier (P)

Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA colliep@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH